The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Survival outcomes in patients (pts) with KRAS/NRAS (RAS) wild-type (WT) metastatic colorectal cancer (mCRC) and non-liver-limited disease (non-LLD): Data from the PRIME study.
Jean-Yves Douillard
Consultant or Advisory Role - Amgen; Boehringer Ingelheim; Merck Serono; Roche
Research Funding - Merck Serono
Josep Tabernero
Consultant or Advisory Role - Amgen; Celgene; Chugai Pharma; ImClone Systems; Lilly; Merck KGaA; Millennium; Novartis; Roche; Sanofi ; Taiho Pharmaceutical
Salvatore Siena
Consultant or Advisory Role - Amgen; AstraZeneca; Bayer; Celgene; Health Genomics; Roche; Sanofi
Marc Peeters
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
Reija Koukakis
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Jan-Henrik Terwey
Employment or Leadership Position - Amgen Europe
Stock Ownership - Amgen
Roger Sidhu
Employment or Leadership Position - Amgen
Stock Ownership - Amgen